[1]徐蕾,胡雁,陈怡雯,等.肿瘤患者抗PD-1/PD-L1治疗继发瘙痒管理的循证实践[J].军事护理,2022,39(08):12-16.[doi:10.3969/j.issn.2097-1826.2022.08.004]
　XU Lei,HU Yan,CHEN Yiwen,et al.Evidence-based Practice in the Management of Secondary Pruritus in Cancer Patients with Anti-PD-1/PD-L1 Therapy[J].Nursing Journal Of Chinese People's Laberation Army,2022,39(08):12-16.[doi:10.3969/j.issn.2097-1826.2022.08.004]
点击复制

肿瘤患者抗PD-1/PD-L1治疗继发瘙痒管理的循证实践
分享到：

《军事护理》[ISSN:2097-1826/CN:31-3186/R]

卷:
39
期数:
2022年08期
页码:
12-16
栏目:
循证护理实践专栏
出版日期:
2022-08-15

文章信息/Info

Title:
Evidence-based Practice in the Management of Secondary Pruritus in Cancer Patients with Anti-PD-1/PD-L1 Therapy
文章编号:
2097-1826(2022)08-0012-05
作者:
徐蕾1; 胡雁1; 陈怡雯2; 倪丽萍2; 陈瑜1
(1.复旦大学护理学院 复旦大学 JBI循证护理中心,上海200032; 2.复旦大学附属中山医院 肿瘤内科,上海 200032)
Author(s):
XU Lei1; HU Yan1;  CHEN Yiwen2; NI Liping2; CHEN Yu1
(1.EBN Center,School of Nursing,Fudan University,Shanghai 200032, China; 2.Oncology Department,Zhongshan Hospital Affiliated to Fudan University,Shanghai 200032, China)
关键词:
免疫检查点抑制剂;  抗PD-1/PD-L1治疗;  免疫相关皮肤不良反应;  瘙痒症;  循证实践
Keywords:
immune checkpoint inhibitors;  anti-PD-1/PD-L1 therapy;  immune-related cutaneous adverse event;  pruritus;  evidence-based practice
分类号:
R47; R828.3
DOI:
10.3969/j.issn.2097-1826.2022.08.004
文献标志码:
A
摘要:
目的 探讨基于最佳证据的肿瘤患者抗PD-1/PD-L1治疗继发瘙痒管理的实践方法并评价其效果。方法 应用JBI证据总结数据库中的抗PD-1/PD-L1治疗继发瘙痒管理最佳证据在上海市某三级甲等医院肿瘤内科开展循证实践,制订审查标准,规范护士对患者瘙痒症状管理行为,比较证据应用前后抗PD-1/PD-L1治疗患者的瘙痒等级、皮肤药物治疗率以及护士证据执行的依从情况等。结果 最佳证据应用前后,肿瘤患者瘙痒G1～G2/G3级发生率由73.3%、26.7%降至46.7%、6.7%; 皮肤用药治疗率由26.7%下降至16.7%; 护士证据执行的依从率均有提高,差异有统计学意义(均P<0.001)。结论 护士通过应用最佳实践证据,规范了抗PD-1/PD-L1治疗继发瘙痒管理行为,提高了护理管理质量,改善了肿瘤患者的临床结局。
Abstract:
Objective To evaluate the best evidence-based practice of anti-PD-1/PD-L1 therapy for the management of secondary pruritus.Methods The best evidence of anti-PD-1/PD-L1 therapy for secondary pruritus management in Joanna Briggs Institute(JBI)evidence summary database was used to carry out evidence-based practice in the Oncology Department of a tertiary A hospital in Shanghai, and to formulate audit criterions and standardize the management behavior of pruritus of nurses. The changes in pruritus grade of patients treated with anti-PD-1/PD-L1,the changes in the rate of skin drug therapy and the compliance of nurses in evidence execution were compared before and after the application of evidence.Results Before and after the application of the best evidence, the incidence of pruritus G1-G2/G3 decreased from 73.3% and 26.7% to 46.7% and 6.7%.The rate of skin drug treatment decreased from 26.7% to 16.7%. The compliance rate of nurses' evidence execution was improved, with statistical significance(P<0.001).Conclusions Through the application of best practice evidence, nurses can standardize the management behavior of anti-PD-1/PD-L1 therapy for secondary pruritus, improve the quality of nursing management, and improve the clinical outcome of patients.

参考文献/References:

[1] BRAHMER J R,LACCHETTI C,SCHNEIDER B J,et al.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy:American society of clinical oncology clinical practice guideline[J].J Clin Oncol,2018,36(17):1714-1768.
[2] ALSAAB H O,SAU S,ALZHRANI R,et al.PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism,combinations,and clinical outcome[J/OL].[2022-04-30].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5572324/.DOI: 10.3389/fphar.2017.00561.
[3] 胡琪,于雪峰,黎雨,等.抗PD-1/PD-L1免疫检查点抑制剂的皮肤免疫相关不良反应的研究进展[J].现代肿瘤医学,2020,28(4):652-655.
[4] SIBAUD V,MEYER N,LAMANT L,et al.Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies[J].Curr Opin Oncol,2016,28(4):254-263.
[5] LE T K,KAUL S,CAPPELLI L C,et al.Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses[J].J Dermatolog Treat,2021,33(3):1691-1695.
[6] 周英凤,胡雁,顾莺,等.基于证据的持续质量改进模式图的构建[J].中国循证医学杂志,2017,17(5):603-606.
[7] 王春青,胡雁.JBI证据预分级及证据推荐级别系统(2014版)[J].护士进修杂志,2015,30(11):964-967.
[8] MUNTYANU A,NETCHIPOROUK E,GERSTEIN W,et al.Cutaneous immune-related adverse events(irAEs)to immune checkpoint inhibitors:a dermatology perspective on management[J].J Cutan Med Surg,2021,25(1):59-76.
[9] SI X,HE C,ZHANG L,et al.Management of immune checkpoint inhibitor-related dermatologic adverse events[J].Thoracic Cancer,2020,11(2):488-492.
[10]GEISLER A N,PHILLIPS G S,BARRIOS D M,et al.Immune checkpoint inhibitor-related dermatologic adverse events[J].J Am Acad Dermatol,2020,83(5):1255-1268.
[11]THOMPSON J A,SCHNEIDER B J,BRAHMER J,et al.Management of immunotherapy related toxicities,version 1.2019[J].J Natl Compr Canc Netw,2019,17(3):255-289.
[12]MAJEM M,GARCIA-MARTINEZ E,MARTINEZ M,et al.SEOM clinical guideline for the management of immune related adverse events in patients treated with immune checkpoint inhibitors(2019)[J].Clin Transl Oncol,2020,22(2):213-222.
[13]National Cancer Institute.Common terminology criteria for adverse events(CTCAE)5.0[EB/OL].[2022-04-20].https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
[14]马艳梅,刘玉,倪宏,等.免疫检查点抑制剂治疗相关不良反应的护理[J].护理研究,2021,35(16):2966-2970.
[15]余杨,路虹,朱小翼.免疫治疗相关皮肤毒性的护理研究进展[J].护士进修杂志,2018,33(19):1751-1755.
[16]丁心静,丁江华.皮肤免疫相关不良事件与PD-1/PD-L1抑制剂临床疗效相关性的研究进展[J].国际肿瘤学杂志,2022,49(4):225-228.
[17]白娟,方红.抗PD-1/PD-L1免疫治疗的皮肤不良反应及其处理[J].中国皮肤性病学杂志,2019,33(7):828-831.
[18]唐淑慧,侯黎莉,王江.非小细胞肺癌患者免疫治疗致皮肤毒性的调查研究[J].护理学杂志,2020,35(16):35-37.
[19]徐莎,刘亚莉.程序死亡受体1抗体(PD-1)治疗恶性肿瘤患者中免疫相关不良反应的观察与护理[J].护士进修杂志,2018,33(4):355-356.

备注/Memo

备注/Memo:
【 收稿日期 】 2022-04-30 【 修回日期 】 2022-06-30
【 基金项目 】 澳大利亚JBI循证卫生保健中心JBI Fellowship证据临床转化科研项目(FNSF202119)
【 作者简介 】 徐蕾,博士,从事循证护理、肿瘤护理工作
【 通信作者 】 陈怡雯,电话:021-64041990
更新日期/Last Update: 2022-08-15